Tag: research

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulations Plus Inc., Dassault Systèmes SE (SIMULIA/BIOVIA), Ansys Inc., Medidata Solutions (Dassault Systèmes), Insilico Medicine Ltd., Unlearn.AI Inc., Applied BioMath LLC, Rosa & Co. LLC, Entelos Inc., Pharsight Corporation (Certara) and others.

GEORGE TOWN, Cayman Islands, June 26, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today announces zero-fee trading across selected spot pairs. Running from June 26 through September 26, 2026, this lowers the cost of every transaction across these markets.

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blaize Holdings, Inc. (NASDAQ: BZAI) resulting from allegations that Blaize may have issued materially misleading business information to the investing public.

FDA-registered manufacturer examines growing use of high-concentration niacinamide formulas and reports that ingredient balance may play a greater role in product performance than active percentage alone.

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.